Covid Vaccine Booster
-
{
- All
- News
- Videos
-
Free Covid Booster Dose For All Adults From Today For Next 75 Days
So far, less than 1 per cent of the target population of 77 crore in the 18-59 age group have been administered the precaution dose, news agency PTI reported.
-
Ahead Of PM's Visit To Jharkhand, Officials Told To Take Covid Booster Jab
Officials and staffers of the Jharkhand government to be deputed on duty for the July 12 visit of Prime Minister Narendra Modi to Deoghar district will receive the precautionary or booster dose of the Covid vaccine today.
-
Delhi Government Offers Free Covid Booster Dose For 18-59 Age Group
Delhi government on Thursday announced that the precautionary or the booster COVID-19 dose will be available for free to all eligible beneficiaries aged between 18 and 59 years in all government vaccination centres.
-
Covid Booster Shots Off To A Slow Start In Delhi
Administering of precaution dose of COVID-19 vaccines began in Delhi on Sunday amid a steady rise in daily case count in the last few days here, even as the pace was sluggish with a few private vaccination centres starting the exercise.
-
Centre Allows Private Centres To Charge Up To Rs 150 Above Vaccine Price
Centre has told the states that the precaution dose will be of the same COVID-19 vaccine as the one used for the administration of the first two doses. Private vaccine centres can charge Rs 150 per dose as service charge above the cost of vaccine.
-
India Starts Vaccinating 12-14 Age Group, Boosters For All Above 60
India has started vaccinating children aged 12 to 14 years from today as it expands its COVID-19 vaccination coverage.
-
Vaccines For 12-14 Age Group From Wednesday, Boosters For All Above 60
India will start vaccinating children aged 12 to 14 years as it expands its COVID-19 vaccination coverage, a media release said today.
-
Covid Booster Efficacy Reduces Significantly By 4th Month: US Study
The efficacy of third doses of the Pfizer and Moderna mRNA vaccines wanes substantially by the fourth month after administration, a new study by the US Centers of Disease Control and Prevention (CDC) said Friday.
-
Moderna Begins Omicron-Specific Vaccine Trials After Pfizer-BioNTech
US biotech company Moderna announced on Wednesday that it has begun clinical trials of a booster dose of vaccine designed specifically to combat the Omicron variant of the coronavirus.
-
Johnson & Johnson Covid Booster Highly Effective Against Severe Omicron: Study
A preliminary South African government study published Thursday showed a booster of the Johnson & Johnson Covid vaccine was 85 percent effective in preventing hospitalization from the Omicron variant, a finding that helps revive the shot's reputatio
-
Decision On Which Covid Vaccine To Be Given As Booster Dose Soon
There have been extensive deliberations on whether the precautionary (third) dose of Covid vaccine for healthcare and frontline workers and citizens above 60 years with comorbidities should be the same as the first two doses.
-
Centre's Notice On COVID-19 Vaccine Booster For Those Above 60 With Co-Morbidity
People aged 60 years and above with co-morbidity will not be required to produce or submit any certificate from doctor at the time of administration of precaution dose of COVID-19 vaccine, the Centre told states and union territories on Tuesday.
-
As Omicron Threat Grows, Countries Shorten Wait Time For Covid Booster
A growing number of countries are reducing the wait time for COVID-19 vaccine boosters from six months to as few as three in a bid to ward off a new surge in infections from the Omicron variant.
-
Expert Panel Considering Evidence On Justification Of Booster Covid Vaccine Dose: Centre
National Expert Group on Vaccine Administration for COVID-19 (NEGVAC) and the National Technical Advisory Group on Immunisation (NTAGI) are considering scientific evidences related to justification for booster doses against Covid.
-
Amid Omicron, Parliamentary Panel Wants Efficacy Of Existing Vaccines Checked
Amid growing concerns over the Omicron variant of SARS-CoV-2, a parliamentary committee has recommended that the efficacy of Covid vaccines must be evaluated and the government conduct more research for booster doses to contain the new strain.
-
Free Covid Booster Dose For All Adults From Today For Next 75 Days
So far, less than 1 per cent of the target population of 77 crore in the 18-59 age group have been administered the precaution dose, news agency PTI reported.
-
Ahead Of PM's Visit To Jharkhand, Officials Told To Take Covid Booster Jab
Officials and staffers of the Jharkhand government to be deputed on duty for the July 12 visit of Prime Minister Narendra Modi to Deoghar district will receive the precautionary or booster dose of the Covid vaccine today.
-
Delhi Government Offers Free Covid Booster Dose For 18-59 Age Group
Delhi government on Thursday announced that the precautionary or the booster COVID-19 dose will be available for free to all eligible beneficiaries aged between 18 and 59 years in all government vaccination centres.
-
Covid Booster Shots Off To A Slow Start In Delhi
Administering of precaution dose of COVID-19 vaccines began in Delhi on Sunday amid a steady rise in daily case count in the last few days here, even as the pace was sluggish with a few private vaccination centres starting the exercise.
-
Centre Allows Private Centres To Charge Up To Rs 150 Above Vaccine Price
Centre has told the states that the precaution dose will be of the same COVID-19 vaccine as the one used for the administration of the first two doses. Private vaccine centres can charge Rs 150 per dose as service charge above the cost of vaccine.
-
India Starts Vaccinating 12-14 Age Group, Boosters For All Above 60
India has started vaccinating children aged 12 to 14 years from today as it expands its COVID-19 vaccination coverage.
-
Vaccines For 12-14 Age Group From Wednesday, Boosters For All Above 60
India will start vaccinating children aged 12 to 14 years as it expands its COVID-19 vaccination coverage, a media release said today.
-
Covid Booster Efficacy Reduces Significantly By 4th Month: US Study
The efficacy of third doses of the Pfizer and Moderna mRNA vaccines wanes substantially by the fourth month after administration, a new study by the US Centers of Disease Control and Prevention (CDC) said Friday.
-
Moderna Begins Omicron-Specific Vaccine Trials After Pfizer-BioNTech
US biotech company Moderna announced on Wednesday that it has begun clinical trials of a booster dose of vaccine designed specifically to combat the Omicron variant of the coronavirus.
-
Johnson & Johnson Covid Booster Highly Effective Against Severe Omicron: Study
A preliminary South African government study published Thursday showed a booster of the Johnson & Johnson Covid vaccine was 85 percent effective in preventing hospitalization from the Omicron variant, a finding that helps revive the shot's reputatio
-
Decision On Which Covid Vaccine To Be Given As Booster Dose Soon
There have been extensive deliberations on whether the precautionary (third) dose of Covid vaccine for healthcare and frontline workers and citizens above 60 years with comorbidities should be the same as the first two doses.
-
Centre's Notice On COVID-19 Vaccine Booster For Those Above 60 With Co-Morbidity
People aged 60 years and above with co-morbidity will not be required to produce or submit any certificate from doctor at the time of administration of precaution dose of COVID-19 vaccine, the Centre told states and union territories on Tuesday.
-
As Omicron Threat Grows, Countries Shorten Wait Time For Covid Booster
A growing number of countries are reducing the wait time for COVID-19 vaccine boosters from six months to as few as three in a bid to ward off a new surge in infections from the Omicron variant.
-
Expert Panel Considering Evidence On Justification Of Booster Covid Vaccine Dose: Centre
National Expert Group on Vaccine Administration for COVID-19 (NEGVAC) and the National Technical Advisory Group on Immunisation (NTAGI) are considering scientific evidences related to justification for booster doses against Covid.
-
Amid Omicron, Parliamentary Panel Wants Efficacy Of Existing Vaccines Checked
Amid growing concerns over the Omicron variant of SARS-CoV-2, a parliamentary committee has recommended that the efficacy of Covid vaccines must be evaluated and the government conduct more research for booster doses to contain the new strain.
